-
1
المؤلفون: Jacques Izopet, Chloé Dimeglio, Florence Nicot, Caroline Lefebvre, Romain Carcenac, Nicolas Jeanne, Stéphanie Raymond
المساهمون: Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Mzembaba, Sandy
المصدر: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (3), pp.718-721. ⟨10.1093/jac/dky495⟩
Journal of Antimicrobial Chemotherapy, 2018, 74 (3), pp.718-721. ⟨10.1093/jac/dky495⟩مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, [SDV]Life Sciences [q-bio], hiv, HIV Infections, Drug resistance, viral load result, MESH: Genotype, Virological response, chemistry.chemical_compound, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Genotype, rna-directed dna polymerase, Pharmacology (medical), 030212 general & internal medicine, genes, MESH: High-Throughput Nucleotide Sequencing, ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: Antiretroviral Therapy, High-Throughput Nucleotide Sequencing, Viral Load, virology, MESH: HIV-1 / genetics, 3. Good health, [SDV] Life Sciences [q-bio], [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Infectious Diseases, Treatment Outcome, genotype determination, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Rilpivirine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: Drug Resistance, Female, MESH: Rilpivirine / pharmacology, MESH: Viral Load, Viral hepatitis, Viral load, Microbiology (medical), medicine.medical_specialty, MESH: Mutation, 030106 microbiology, MESH: HIV Infections / drug therapy, MESH: Highly Active, Genome, Viral, MESH: HIV-1 / drug effects, MESH: Viral, MESH: Rilpivirine / therapeutic use, 03 medical and health sciences, massively-parallel genome sequencing, Internal medicine, Drug Resistance, Viral, medicine, MESH: HIV Infections / virology, Humans, MESH: Genome, Genotyping, plasma, Pharmacology, business.industry, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Regimen, chemistry, Mutation, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, HIV-1, business
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::803e02fe658eba4c3b08ac8052064348
https://pubmed.ncbi.nlm.nih.gov/30535228 -
2
المؤلفون: Sculier, Delphine, Gayet-Ageron, Angèle, Battegay, Manuel, Cavassini, Matthias, Fehr, Jan, Hirzel, Cedric, Schmid, Patrick, Bernasconi, Enos, Calmy, Alexandra, Swiss HIV Cohort Study
المساهمون: University of Zurich, Sculier, Delphine, Swiss HIV Cohort Study
المصدر: BMC Infectious Diseases, Vol. 17, No 1 (2017) P. 476
Sculier, Delphine; Gayet-Ageron, Angèle; Battegay, Manuel; Cavassini, Matthias; Fehr, Jan; Hirzel, Cédric; Schmid, Patrick; Bernasconi, Enos; Calmy, Alexandra (2017). Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC infectious diseases, 17(1), p. 476. BioMed Central 10.1186/s12879-017-2579-2 <http://dx.doi.org/10.1186/s12879-017-2579-2>
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-10 (2017)
BMC infectious diseases, vol. 17, no. 1, pp. 476
BMC Infectious Diseasesمصطلحات موضوعية: Cyclopropanes, 0301 basic medicine, Male, Human immunodeficiency virus (HIV), HIV Infections, Pharmacology, medicine.disease_cause, 10234 Clinic for Infectious Diseases, chemistry.chemical_compound, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Emtricitabine, Medicine, 030212 general & internal medicine, Prospective Studies, 610 Medicine & health, Prospective cohort study, ddc:616, virus diseases, Emtricitabine/therapeutic use, Virological response, Middle Aged, Viral Load, Drug Combinations, Infectious Diseases, Treatment Outcome, Alkynes, Rilpivirine, Female, Safety, Viral load, Research Article, medicine.drug, Cohort study, Adult, medicine.medical_specialty, HIV-1/genetics, Efavirenz, Highly Active/methods, Anti-HIV Agents, HIV Infections/drug therapy, Antiretroviral Therapy, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Internal medicine, Tenofovir/therapeutic use, Humans, lcsh:RC109-216, Tenofovir, First-line regimen, ddc:613, business.industry, Benzoxazines/adverse effects, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), 2725 Infectious Diseases, 030112 virology, Benzoxazines, Discontinuation, CD4 Lymphocyte Count, chemistry, Treatment simplification, Anti-HIV Agents/therapeutic use, Rilpivirine/therapeutic use, HIV-1, business
وصف الملف: 12879_2017_Article_2579.pdf - application/pdf; application/pdf
